Phase I Safety and Tolerability Study of Human Monoclonal Antibody 5B1 (MVT-5873) as Monotherapy and With Chemotherapy in Subjects With Pancreatic Cancer or Other CA19-9 Positive Malignancies.

Trial Profile

Phase I Safety and Tolerability Study of Human Monoclonal Antibody 5B1 (MVT-5873) as Monotherapy and With Chemotherapy in Subjects With Pancreatic Cancer or Other CA19-9 Positive Malignancies.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs 5B1 (Primary) ; Gemcitabine; Paclitaxel
  • Indications Colon cancer; Pancreatic cancer
  • Focus Adverse reactions; First in man
  • Sponsors MabVax Therapeutics
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Results (n=25; as of 2 Feb 2017) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2017 According to a MabVax Therapeutics media release, the dose escalation portion of this trial has been completed and a second arm of this trial is actively evaluating MVT-5873 in combination with gemcitabine plus nab-paclitaxel in newly diagnosed pancreatic cancer patients.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top